XML 108 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Research and Development Agreements - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 24, 2023
USD ($)
Oct. 23, 2020
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2014
Dec. 31, 2022
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2023
USD ($)
milestone
Dec. 31, 2022
USD ($)
milestone
Dec. 31, 2021
USD ($)
milestone
Disaggregation of Revenue [Line Items]                  
Collaboration revenue             $ 17,157,000 $ 10,287,000 $ 63,175,000
GSK                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue             17,200,000 10,300,000 63,200,000
GSK | Collaborative Research and Development Agreement | Minimum                  
Disaggregation of Revenue [Line Items]                  
Royalty percent on net sales       4.00%          
GSK | Collaborative Research and Development Agreement | Maximum                  
Disaggregation of Revenue [Line Items]                  
Royalty percent on net sales       8.00%          
GSK | Collaborative Research and Development Agreement | Anti-PD-1 (Jemperli/Dostarlimab)                  
Disaggregation of Revenue [Line Items]                  
Agreement term following first commercial sale or expiration of the last to expire patent (in years)   12 years              
GSK | Phase 3 clinical trial initiation - first indication | Anti-PD-1 (Jemperli/Dostarlimab)                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue           $ 5,000,000.0      
GSK | Phase 3 clinical trial initiation - first indication | Anti-TIM-3 (GSK4069889A/Cobolimab)                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue         $ 5,000,000.0     $ 5,000,000  
Number of milestones achieved during period | milestone               1  
GSK | Royalty Agreement                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue             17,200,000 $ 5,300,000 3,200,000
GSK | Royalty Agreement, up To $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab)                  
Disaggregation of Revenue [Line Items]                  
Royalty percent on net sales   8.00%              
Royalty sales   $ 1,000,000,000              
GSK | Royalty Agreement, above $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab)                  
Disaggregation of Revenue [Line Items]                  
Royalty sales   $ 1,000,000,000              
GSK | Royalty Agreement, above $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab) | Minimum                  
Disaggregation of Revenue [Line Items]                  
Royalty percent on net sales   12.00%              
GSK | Royalty Agreement, above $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab) | Maximum                  
Disaggregation of Revenue [Line Items]                  
Royalty percent on net sales   25.00%              
GSK | JEMPERLI Royalty Monetization Agreement                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue             13,800,000 2,300,000  
Non cash royalty revenue, for sale of future royalties               2,300,000  
GSK | Zejula Revenue                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue               1,600,000  
GSK | Zejula Royalty Monetization Agreement                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue             3,400,000 1,400,000  
GSK | Milestone Agreements                  
Disaggregation of Revenue [Line Items]                  
Collaboration revenue             $ 0 $ 5,000,000 $ 60,000,000
Number of milestones achieved during period | milestone             0 1 4
Centessa | Collaborative Research and Development Agreement                  
Disaggregation of Revenue [Line Items]                  
Potential future payments $ 10,000,000   $ 10,000,000       $ 10,000,000    
Centessa | Collaborative Research and Development Agreement | License Agreement, Centessa Pharmaceuticals (UK) Limited                  
Disaggregation of Revenue [Line Items]                  
Cash payment 4,000,000   7,000,000            
Reimbursement $ 3,000,000                
Transaction costs incurred     300,000            
Total transaction     $ 7,300,000